Could Abeona Therapeutics Incorporated (NASDAQ:ABEO) See a Reversal After Less Sellers Came In?

December 20, 2017 - By Stephen Andrade

 Could Abeona Therapeutics Incorporated (NASDAQ:ABEO) See a Reversal After Less Sellers Came In?

The stock of Abeona Therapeutics Incorporated (NASDAQ:ABEO) registered a decrease of 12.5% in short interest. ABEO’s total short interest was 6.64 million shares in December as published by FINRA. Its down 12.5% from 7.59 million shares, reported previously. With 735,800 shares average volume, it will take short sellers 9 days to cover their ABEO’s short positions. The short interest to Abeona Therapeutics Incorporated’s float is 30.83%.

The stock increased 0.82% or $0.125 during the last trading session, reaching $15.325. About 606,186 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 151.02% since December 20, 2016 and is uptrending. It has outperformed by 134.32% the S&P500.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $716.83 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics has $34 highest and $6.0 lowest target. $25.88’s average target is 68.87% above currents $15.325 stock price. Abeona Therapeutics had 30 analyst reports since December 16, 2015 according to SRatingsIntel. The rating was maintained by FBR Capital on Thursday, May 25 with “Buy”. The rating was maintained by Cantor Fitzgerald on Thursday, October 12 with “Overweight”. Cantor Fitzgerald maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Monday, June 5 with “Buy” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, July 18. H.C. Wainwright maintained the shares of ABEO in report on Wednesday, July 19 with “Buy” rating. Maxim Group maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Tuesday, July 18 with “Buy” rating. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Friday, January 6 by Jefferies. The rating was maintained by H.C. Wainwright on Monday, October 16 with “Buy”. On Wednesday, December 16 the stock rating was initiated by Maxim Group with “Buy”. The rating was initiated by Cantor Fitzgerald on Thursday, September 8 with “Buy”.

More important recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: Streetinsider.com which released: “Form 4 ABEONA THERAPEUTICS INC. For: Dec 14 Filed by: Alvino Mark” on December 18, 2017, also Seekingalpha.com published article titled: “Relieving Suffering From Genetic Disease – Abeona Therapeutics”, Prnewswire.com published: “Biotech Stocks’ Research Reports Released on PhaseRx, Abeona Therapeutics …” on December 08, 2017. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) was released by: Seekingalpha.com and their article: “Abeona Therapeutics’ (ABEO) CEO Tim Miller on Q3 2017 Results – Earnings Call …” with publication date: November 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.